Product Description
Fexinidazole is a Nitroimidazole Antimicrobial. The mechanism of action of fexinidazole is as a Cytochrome P450 1A2 Inhibitor, and Cytochrome P450 2B6 Inhibitor, and Cytochrome P450 2C19 Inhibitor, and Cytochrome P450 2D6 Inhibitor, and Cytochrome P450 3A4 Inhibitor, and Cytochrome P450 3A5 Inhibitor, and Cytochrome P450 1A2 Inducer, and Cytochrome P450 2B6 Inducer, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Organic Cation Transporter 2 Inhibitor, and Organic Anion Transporter 1 Inhibitor, and Organic Anion Transporter 3 Inhibitor, and Multidrug and Toxin Extrusion Transporter 1 Inhibitor, and Multidrug and Toxin Extrusion Transporter 2 K Inhibitor. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Fexinidazole)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: United States
Approved Indications: Trypanosomiasis | Trypanosomiasis, African
Known Adverse Events: Abdominal Pain | Back Pain | Dizziness | Headache | Pain Unspecified | Tremor | Insomnia | Hyperkalemia | Hypocalcemia | Asthenia | Dyspepsia
Company: Drugs for Neglected Diseases initiative (DNDi)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, France
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Liver Cirrhosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| POP17145 | P1 |
Completed |
Liver Cirrhosis |
2023-05-03 |
21% |